Company profile
Annual Report 2013
LEI
cee stock exchange group
Issuers / Issuers News
Article print

13 Sep 2013 14:15 
Extraordinary Information
Marketing authorisation for biosimilar infliximab in EU
Attached documents:
Releaser: EGIS Pharmaceuticals PLC
Date Issued: 13 Sep 2013
 
Actual
2014 average
Name
Price
%
Turn. (tEUR)
^
866
+0.58
3
-
180
0.00
13
^
71
+10.94
15
ˇ
201
-0.99
117
-
5,300
0.00
0
ˇ
717
-0.42
3
ˇ
12,320
-0.48
333
^
339
+0.30
67
^
4,007
+0.30
350
^
322
+0.63
4
^
1,100
+1.38
5
ˇ
3,832
-0.75
676
^
113
+6.60
14
^
4,600
+1.55
70
Change %: to baseprice
Data delayed by 15 minutes
Indices
Index
Value
Change %
BUX
17,577.23
-29.64 (-0.17)
1,465.47
-5.60 (-0.38)
1,141.58
0.88 (0.08)
1,132.41
0.70 (0.06)
1,835.54
8.66 (0.47)